Boiron Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest, by SHB SOCIETE HENRI BOIRON SA, was filed 22 Mar 2021.
Boiron: what insiders have been doing
Boiron is a Healthcare & Pharma company. Its directors and officers file their transactions with AMF. Nothing new has been filed by managers of Boiron in twelve months, the latest record being from 26 October 2023.
Since 2021, the database holds 1 purchase and 12 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Since the insiders bought
- +6.4%Entry €36.70 · Close at T+365 €39.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 462,964 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934859
- 272,184 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934860
- 5,900 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934862
- 198,664 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934863
- 2,978 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934864
- 858,660 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934854
- 4,748 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934855
- 4,748 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934857
- 4,748 shares@ €39.64100.0% of flowActionHors plateforme de négociationISIN FR00000611292023DD934858
- 3,267,121 shares@ €39.6498.1% of flowActionEuronext ParisISIN FR00000611292023DD934820
- 20,000 shares@ €35.490.5% of flowActionEuronext ParisISIN FR00000611292021DD737878
- 20,000 shares@ €35.49100.0% of flowActionEuronext ParisISIN FR00000611292021DD737486Canonical exit: 14 Jun 2021 (T+90)
- 50,000 shares@ €35.82951.4% of flowActionEuronext ParisISIN FR00000611292021DD736784
13 of 13 declarations
About Boiron
Boiron is a leading French pharmaceutical group historically specialized in homeopathy and listed on Euronext Paris under ISIN FR0000061129 (ticker BOI). The company was founded in 1932, when pharmacists Jean and Henri Boiron started producing homeopathic medicines to meet physicians’ demand for high-quality products. Headquartered in Messimy, in the Rhône region near Lyon, Boiron combines a strong French industrial base with an international commercial footprint supported by subsidiaries and distributor networks. The company’s official materials also note that homeopathy was incorporated into the French pharmacopoeia in 1965, later into the U.S. pharmacopoeia in 1982 and the European pharmacopoeia in 1995.
Boiron’s core business remains homeopathic healthcare products. Its portfolio is built around non-proprietary homeopathic medicines, homeopathic specialties and, more recently, other health products. The group presents itself as a global expert in homeopathy, with more than 90 years of experience, and emphasizes pharmaceutical-grade manufacturing, rigorous quality control and traceability. One notable feature of the business model is its control over the sourcing and production chain: the company states that a large share of its plant stocks comes from Europe, mainly France. That industrial discipline is a key competitive advantage in a highly regulated and niche market.
Read moreShow less
Geographically, Boiron is not limited to its domestic market. Although France remains its historic base, the group reports meaningful sales in Europe outside France, North America and other countries, showing a diversified international commercial presence. Recent commercial disclosures highlight that sales are split across these regions, which helps reduce dependence on any single market and reflects the company’s long-standing export orientation. This international reach is particularly important for a company whose brand is closely associated with homeopathy and pharmacy-driven distribution.
From a corporate and shareholder standpoint, Boiron is a notable family-controlled listed company in the French healthcare universe. In 2023, the family shareholders announced their intention to launch a simplified tender offer, followed by the definitive transfer of majority control to Boiron Développement in 2024. The group also published its 2024 annual financial report, underlining its ongoing regulatory disclosure and market presence. Overall, Boiron can be viewed as a defensive healthcare stock with a distinctive positioning at the intersection of pharmacy, homeopathic medicines and health solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
